Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda gains non-exclusive access to Alnylam’s RNAi therapeutics platform in oncology and metabolic disease for $150 million upfront.